Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPLISAV-B vs Engerix-B in adults 18-70
NCT02117934Phase 3Completed
- Sponsor
- Dynavax Technologies
- Start
- Apr 2014
- Primary completion
- Oct 2015
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of Heplisav-B in hepatitis B (HBV), sponsored by Dynavax Technologies. Started Apr 2014; status: completed.
02
Drugs
Heplisav-B
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02117934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117934.